BioPharma Resources

Drug Trial Radar · NCT07768371

A 52-week Study of Remibrutinib in IgE-mediated Food Allergy

A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy and Safety of Remibrutinib (LOU064) in Adult and Adolescent Participants With IgE-mediated Food Allergy

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 576 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

576

Planned (sponsor's estimate)

Start

Aug 27, 2026

Primary completion

Mar 30, 2029

Study completion Dec 31, 2029

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin E (IgE)- mediated allergy in comparison to placebo.

Conditions

  • IgE-Mediated Food Allergy
  • Peanut Allergy
  • Cow Milk Allergy
  • Egg Allergy

Interventions

  • RemibrutinibDrug

    Oral administration of remibrutinib.

  • PlaceboDrug

    Oral administration of placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sub-study 1: Number of participants achieving response status (tolerated at least 600 mg of peanut protein)Time frame: Week 24
  2. Sub-study 2: Number of participants achieving response status (tolerated at least 1000 mg of milk protein)Time frame: Week 24
  3. Sub-study 3: Number of participants achieving response status (tolerated at least 1000 mg of egg protein)Time frame: Week 24

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • AllerVie Clinical Research-Homewood

    Birmingham, Alabama · Recruiting

  • University of Alabama at Birmingham

    Birmingham, Alabama · Recruiting

  • Medical Resch of Arizona-Div of Allergy Asthma and Immunology

    Scottsdale, Arizona · Recruiting

  • Arkansas Childrens Hosp Rsch Inst

    Little Rock, Arkansas · Recruiting

  • California Allergy and Asthma Medical Group

    Los Angeles, California · Recruiting

  • Stanford Univ Sean N Parker Center for Allergy and Asthma Re

    Palo Alto, California · Recruiting

  • Asthma and Allergy Associates P C

    Colorado Springs, Colorado · Recruiting

  • Childrens Healthcare Of Atlanta

    Atlanta, Georgia · Recruiting

  • Sneeze Wheeze Itch Asso LLC

    Normal, Illinois · Recruiting

  • Asthma and Allergy Center of Chicago S C

    River Forest, Illinois · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Institute for Asthma and Allergy PC

    Chevy Chase, Maryland · Recruiting

  • Boston Childrens Hospital

    Boston, Massachusetts · Recruiting

  • Respiratory Medicine Research Institute of Michigan

    Ypsilanti, Michigan · Recruiting

  • Impact Medical - Circuit Clinical

    Riverdale, New Jersey · Recruiting

  • Northwell Health

    New York, New York · Recruiting

  • Montefiore Health System

    The Bronx, New York · Recruiting

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • National Allergy and Asthma Research LLS

    North Charleston, South Carolina · Recruiting

  • Western Sky Medical Research

    El Paso, Texas · Recruiting

  • Allergy Associates of Utah

    Sandy City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.